
Global R&D Pipeline
My Favorite
Hot Targets:
GD2
Back
Total number of drugs
92
Phase II and later clinical stages
7.6%
Involving companies
87
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D2-targeting CAR program (Hrain Biotechnology) | D2-targeting CAR program (Hrain Biotechnology) | Cell therapy | Disialoganglioside GD2 modulators | Hrain Biotechnology Co., Ltd. | Hrain Biotechnology Co., Ltd. | Discovery | Discovery | D2-targeting CAR program (Hrain Biotechnology) | detail > | ||||||||||||
| OGD-201 | OGD-201 | Monoclonal antibody | Neoplasms Other Diseases | Disialoganglioside GD2 inhibitors | OGD2 Pharma SAS | OGD2 Pharma SAS | Preclinical | OGD-201 | detail > | ||||||||||||
| OGD-203 | OGD-203 | CAR-T | Neoplasms Nervous System Diseases Other Diseases | Disialoganglioside GD2 inhibitors | OGD2 Pharma SAS | OGD2 Pharma SAS | Preclinical | OGD-203 | detail > | ||||||||||||
| Qβ-9NHAc-GD2 | Qβ-9NHAc-GD2 | Recombinant vector vaccine Therapeutic vaccine | Neoplasms | Disialoganglioside GD2 modulators | Shandong UniversityIaso Therapeutics, Inc.Michigan State University | Shandong UniversityIaso Therapeutics, Inc.Michigan State University | Preclinical | Preclinical | Qβ-9NHAc-GD2 | detail > | |||||||||||
| TB-302 | TB-302 | CAR-NK Induced pluripotent stem cells (iPSC) | Neoplasms Nervous System Diseases Other Diseases | Disialoganglioside GD2 inhibitors | Therabest, INC. | ViGenCell, Inc.Therabest, INC. | Preclinical | TB-302 | detail > | ||||||||||||
| CN118416062 | CN118416062 | Monoclonal antibody | Neoplasms Other Diseases | Tianjin Medical University Cancer Institute and Hospital | Tianjin Medical University Cancer Institute and Hospital | Discovery | CN118416062 | detail > | |||||||||||||
| WO2023205646 | WO2023205646 | CAR-T | Neoplasms | Wisconsin Alumni Research Foundation | Wisconsin Alumni Research Foundation | Discovery | WO2023205646 | detail > | |||||||||||||
| Anti-GD2 chimeric antigen receptor T cell therapy(Pell Bio-Med Technology) | Anti-GD2 chimeric antigen receptor T cell therapy(Pell Bio-Med Technology) | CAR-T | Neoplasms Nervous System Diseases | Disialoganglioside GD2 inhibitors Immunologic cytotoxicity T lymphocyte replacements | Pell Bio-Med Technology Co., Ltd. | Preclinical | Anti-GD2 chimeric antigen receptor T cell therapy(Pell Bio-Med Technology) | detail > | |||||||||||||
| Anti-GD2 CAR-T (National Cancer ) | Anti-GD2 CAR-T (National Cancer ) | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases Other Diseases | Disialoganglioside GD2 inhibitors | National Cancer Institute | Phase 1 | Anti-GD2 CAR-T (National Cancer ) | detail > | |||||||||||||
| MB-CART GD2-IL18 | MB-CART GD2-IL18 | CAR-T | Neoplasms Nervous System Diseases Other Diseases | Disialoganglioside GD2 inhibitors | Miltenyi Biomedicine GmbH | Miltenyi Biomedicine GmbH | Preclinical | MB-CART GD2-IL18 | detail > |
Total 92 data
1
2
3
4
5
6
...
9
10


